News Sentiment

RYTM sentiment intelligence

Rhythm Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 106.60 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

77/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-1.7% over one week, +10.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Negative

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 77/100 classification
One-week reaction -1.7% Price digesting
Trend fit Trend inactive 10.1% over four weeks
Fair value 67.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 6
TradingView 5
Moomoo 4
GlobeNewswire 4
simplywall.st 3
DirectorsTalk Interviews 2
Sahm 2

Event Lens

What the news is about

Classified themes
Earnings 30
Market update 22
Analyst action 5
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
PR Newswire Direct company coverage

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating whether officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties due to potential self-dealing. Long-term shareholders are encouraged to contact the firm to discuss potential damages and corporate gover

Tone
Negative 29/100
Event
Market update
Published
21 Jul 2026 21:10
Source
PR Newswire
Ad-hoc-news.de Direct company coverage

RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth

Rhythm Pharmaceuticals (RYTM) stock is trading within its recent range as the company reports double-digit revenue growth for its rare obesity therapy, setmelanotide. Q1 2026 revenue reached $29 million, up 38% year-over-year, driven by increased patient uptake. While the company

Tone
Positive 73/100
Event
Earnings
Published
21 Jul 2026 19:14
Source
Ad-hoc-news.de
The Manila Times Direct company coverage

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Rhythm Pharmaceuticals, Inc. announced it will host a conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a corporate update. The company is a commercial-stage biopharmaceutical firm focused on r

Tone
Neutral 50/100
Event
Earnings
Published
21 Jul 2026 12:10
Source
The Manila Times
Stock Titan Direct company coverage

Rhythm Pharmaceuticals schedules live Q2 results webcast Aug. 4

Rhythm Pharmaceuticals (Nasdaq: RYTM) will report its second-quarter 2026 financial results and provide a corporate update during a live conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET. The company, a commercial-stage biopharmaceutical firm, focuses on rar

Tone
Neutral 50/100
Event
Earnings
Published
21 Jul 2026 12:10
Source
Stock Titan
DirectorsTalk Interviews Direct company coverage

Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside

Rhythm Pharmaceuticals, Inc. (RYTM) is a biopharmaceutical company focusing on treatments for rare neuroendocrine diseases, driving investor interest with strong analyst ratings and growth potential. Despite current negative EPS and high R&D costs, its 83.8% revenue growth and fl

Tone
Positive 75/100
Event
Earnings
Published
21 Jul 2026 01:10
Source
DirectorsTalk Interviews
Pluang Direct company coverage

Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating officers and directors of Rhythm Pharmaceuticals, Inc. for alleged breaches of fiduciary duties through potential self-dealing. This investigation could result in damages for shareholders and corporate governance reforms. Long-term shareholders ar

Tone
Negative 9/100
Event
Regulatory and legal
Published
17 Jul 2026 01:13
Source
Pluang
Kavout | AI Direct company coverage

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

Rhythm Pharmaceuticals' drug, setmelanotide, shows promising Phase 3 results for acquired hypothalamic obesity (HO), targeting a potential FDA approval by March 20, 2026. This condition represents a significant unmet medical need with a substantial global patient population. Anal

Tone
Positive 72/100
Event
Earnings
Published
16 Jul 2026 23:39
Source
Kavout | AI
TradingView Direct company coverage

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – BMV:RYTM

This article provides the enterprise value to revenue forward metric for Rhythm Pharmaceuticals, Inc. (BMV:RYTM). It is presented on TradingView, a financial platform offering various market data and analysis tools. The information indicates the financial metric as of the specifi

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 22:47
Source
TradingView
Investing.com South Africa Direct company coverage

Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data By Investing.com

Citizens has reaffirmed its Market Outperform rating and $155 price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) based on strong Imcivree launch data, particularly in hypothalamic obesity. Endocrinologist surveys suggest better-than-expected sales, leading Citizens to raise it

Tone
Positive 74/100
Event
Analyst action
Published
14 Jul 2026 10:40
Source
Investing.com South Africa
Investing.com Direct company coverage

Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data

Citizens has reiterated a Market Outperform rating and $155.00 price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) due to strong Imcivree launch data. A recent endocrinologist survey shows the drug performing well in hypothalamic obesity, suggesting potential for a strong sales

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 09:52
Source
Investing.com
DirectorsTalk Interviews Direct company coverage

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 28.91% Upside Potential in Biotechnology

Rhythm Pharmaceuticals (RYTM) is a biopharmaceutical company focusing on rare neuroendocrine diseases, notably with its lead product IMCIVREE. The company shows strong market potential with a $7.44 billion market cap, significant revenue growth of 83.80%, and positive analyst sen

Tone
Positive 75/100
Event
Earnings
Published
13 Jul 2026 09:11
Source
DirectorsTalk Interviews
TradingView Direct company coverage

Price to earnings forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM

This article provides financial data for Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), specifically focusing on its forward price-to-earnings ratio. It indicates that the company is listed on the Nasdaq Stock Market and that the market was closed with no trades at the time of publ

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 17:40
Source
TradingView
Sahm Direct company coverage

Rhythm Pharmaceuticals (RYTM) On TRANSCEND And New Approvals, Buying Opportunity Or Priced In?

Rhythm Pharmaceuticals (RYTM) is gaining attention after positive Phase 3 TRANSCEND trial results for setmelanotide and recent US and European regulatory approvals. Despite a significant stock price increase, analysts believe the stock is 18% undervalued, with a fair value of $13

Tone
Positive 63/100
Event
Earnings
Published
09 Jul 2026 21:13
Source
Sahm
TradingView Direct company coverage

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – XETR:1RV

This article focuses on the enterprise value to revenue forward for Rhythm Pharmaceuticals, Inc. (XETR:1RV). It is a financial overview of the company, likely providing data or analysis related to this specific valuation metric. The content was provided by FactSet Research System

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 16:41
Source
TradingView
GlobeNewswire Direct company coverage

Rhythm Pharmaceuticals Announces The New England Journal of

Rhythm Pharmaceuticals announced that results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for acquired hypothalamic obesity were published in The New England Journal of Medicine. The study demonstrated robust improvements in weight and hunger, with setmelano

Tone
Positive 72/100
Event
Earnings
Published
09 Jul 2026 09:10
Source
GlobeNewswire
Bitget Direct company coverage

Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine.

Rhythm Pharmaceuticals Inc. announced the publication of its Phase 3 Transcend clinical trial results for acquired hypothalamic obesity in The New England Journal of Medicine. This publication highlights the efficacy and safety of their investigational therapy for severe obesity

Tone
Positive 73/100
Event
Regulatory and legal
Published
09 Jul 2026 08:41
Source
Bitget
Yahoo! Finance Canada Direct company coverage

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced the publication of its Phase 3 TRANSCEND trial results for setmelanotide in acquired hypothalamic obesity in The New England Journal of Medicine. The study demonstrated significant reductions in BMI and improvements in hunger in patients, leading

Tone
Positive 73/100
Event
Earnings
Published
09 Jul 2026 08:41
Source
Yahoo! Finance Canada
Quiver Quantitative Direct company coverage

Rhythm Pharmaceuticals Announces NEJM Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced that the New England Journal of Medicine (NEJM) published results from its pivotal Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity. The study, the largest and longest placebo-controlled trial for this condition, demonstr

Tone
Positive 74/100
Event
Earnings
Published
08 Jul 2026 21:20
Source
Quiver Quantitative
Moomoo Direct company coverage

Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society >RYTM

Rhythm Pharmaceuticals will present new data on acquired hypothalamic obesity (AHO) at the Pediatric Endocrine Society Annual Meeting. These presentations will include real-world data highlighting the impact of AHO on patients and families, as well as an analysis of the genetic c

Tone
Positive 71/100
Event
Market update
Published
06 Jul 2026 20:13
Source
Moomoo
TradingView Direct company coverage

Price to sales forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM

This page displays financial information for Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) on TradingView, specifically focusing on its price-to-sales forward metric. The content includes an overview of the company's market data, financial health, and other related services offered

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 12:39
Source
TradingView
Finviz Direct company coverage

RYTM - Rhythm Pharmaceuticals Inc Options

This article provides a detailed financial overview of Rhythm Pharmaceuticals Inc (RYTM), including its stock performance, key financial metrics, and analyst ratings. It covers market capitalization, sales, income, various ratios, and insider/institutional ownership, alongside re

Tone
Positive 59/100
Event
Analyst action
Published
04 Jul 2026 20:13
Source
Finviz
MSN Direct company coverage

Rhythm Pharmaceuticals announces public offering of common stock

Rhythm Pharmaceuticals has announced a public offering of its common stock. The company is making this offering to raise capital. Further details about the offering size or expected use of proceeds were not provided in this snippet.

Tone
Negative 40/100
Event
Market update
Published
04 Jul 2026 01:09
Source
MSN
GuruFocus Direct company coverage

Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript

Rhythm Pharmaceuticals Inc. will discuss interim six-month Phase 2 results for Setmelanotide during an upcoming call. The transcript indicates the call will feature a presentation followed by a question-and-answer session, where participants can ask questions by pressing star 11.

Tone
Positive 59/100
Event
Earnings
Published
03 Jul 2026 20:10
Source
GuruFocus